Rexulti

Pharma

Axsome increases Auvelity's peak sales projection to $8B

A few days after gaining an FDA expansion for Auvelity to treat Alzheimer’s disease agitation, Axsome has projected its peak sales to reach $8 billion.

Kevin Dunleavy May 5, 2026 11:48am

Axsome's Auvelity wins FDA expansion for Alzheimer's agitation

May 1, 2026 11:42am

After Avadel setback, Lundbeck signals future M&A rigor

Jan 22, 2026 11:13am

brain amyloid alzheimers strings detailed web complicated thought

Lundbeck, Otsuka back survey on Alzheimer's agitation

Nov 12, 2025 12:07pm

TV drug ad spending picked up in September despite crackdown

Oct 7, 2025 6:25am

Celltrion buy, Rexulti CRL, Glenmark-Hengrui—Fierce Pharma Asia

Sep 26, 2025 10:00am